

To whom it may concern

Company Name: Innovacell Inc.
Representative: Representative Director Co-CEO
Colin Novick
Representative: Representative Director Co-CEO
Jason Sieger
(Code No.: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director CFO Yasushi Hosono
(<https://innovacell.com/contact/?lang=en>)

Notice Regarding the Commencement of Periodic Disclosure of ICEF15 Trial Enrollment Updates

Innovacell Inc. hereby announces that it has decided to periodically disclose the number of randomized patients (preliminary figures) in the ongoing multi-regional Phase III clinical trial for ICEF15, one of the development candidates in the Innovacell group's pipeline.

■ Background to the Periodic Disclosure of Patient Randomized Figures

ICEF15 is the most advanced development candidate in Innovacell group's pipeline, and we are currently conducting a multi-regional Phase III clinical trial (hereinafter referred to as the "Fidelia Trial") for ICEF15 in 11 European countries and Japan.

Innovacell group plans to complete patient randomization in the Fidelia Trial by the end of the fiscal year 2026, and to date, we have reported the latest number of randomized patients in the Fidelia trial as opportunities arose, such as in the Consolidated Financial Results for the First Quarter of the Fiscal Year 2026 and the First Quarter Progress Update Video for the Fiscal Year 2026.

To provide a timelier update on the latest progress in ICEF15 clinical development, we will begin disclosing the latest number of randomized patients (preliminary numbers based on CRO reports) on Innovacell Inc.'s corporate website approximately once every two weeks, starting today. To the best of our knowledge, the periodic disclosure of the number of patients randomized in an ongoing clinical trial conducted by a biotech is a practice that has rarely been seen to date. We hope these updates will help investors better understand the latest progress of ICEF15 and provide useful reference information when evaluating the Company's disclosures

Disclosure URL: <https://innovacell.com/business/pipeline/icef15/?lang=en>

Start Date : June 22, 2026

■ Overview of ICEF15

ICEF15, the most advanced of the Innovacell group's pipeline products, aims to treat urge fecal incontinence by repairing and regenerating muscle tissue through the local administration of a patient's own skeletal myoblasts.

Fecal incontinence is defined as the involuntary or unintentional leakage of stool from the anus, and it is estimated that approximately 5 million people in Japan suffer from fecal incontinence (Source: website of The Japan Society of Coloproctology). Urge fecal incontinence is characterized primarily by the inability to defer defecation long enough to reach the toilet despite feeling the urge to defecate, and it is considered to be commonly caused by dysfunction of the external anal sphincter. According to a study published in the Journal of the Japan Society of Coloproctology (Toshiki Mimura

et al., "Survey Report on the Actual Status of Fecal Incontinence Care in Japan—Current Status of Diagnosis and Treatment—," Journal of the Japan Society of Coloproctology, 65: 101–108, 2012), slightly more than half (approximately 51%) of fecal incontinence patients have urge-type symptoms.

■ **About Innovacell Inc.** (<https://innovacell.com/?lang=en>)

The predecessor of Innovacell Inc. was a cell therapy start-up company spun out from the Medical University of Innsbruck (Austria). Innovacell Inc. was established in Japan in 2021 as the parent company of said Austrian company (currently Innovacell GmbH).

Innovacell group aims to improve patient health and QOL through the development and commercialization of cell therapies and regenerative medicine. It is currently focused on developing and commercializing regenerative medicine products for the treatment of urge and passive fecal incontinence as well as stress urinary incontinence.

ICEF15, the most advanced of the Group's pipeline products, aims to treat urge fecal incontinence by regenerating muscle tissue via the local administration of a patient's own skeletal myoblasts. ICEF15 is currently undergoing a multi-regional Phase III clinical trial in 11 European countries and Japan.

To date, Innovacell GmbH has completed multiple clinical trials in Europe, including Phase IIb trials for ICEF15 (urge fecal incontinence) and ICES13 (stress urinary incontinence).

End